Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

316

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2028

Conditions

Locally Advanced Breast Cancer

Interventions

DRUG

pyrotinib

pyrotinib 400 mg, orally once daily for one year

Trial Locations (1)

RECRUITING

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors

lead

RenJi Hospital

OTHER

NCT04254263 - Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer | Biotech Hunter | Biotech Hunter